Non-Oncology Precision Medicine Market Size, Share, and Industry Analysis, By Type (Diagnostics {Next-generation Sequencing (NGS), Polymerase Chain Reaction (PCR), and Others}, Therapeutics { Antibody-Drug Conjugates (ADCs), Kinase inhibitors, and Others}, and Research {Single-Cell Sequencing, Next-generation Sequencing (NGS), and Others), By Application (Rare Diseases, Neurological Disorders, Cardiovascular Disorders, Infectious Diseases, and Others), By End-user (Pharmaceutical & Biotechnology Companies, Contract Research Organizations , and Others), and Region Forecast, 2024-2032

Non-oncology precision medicine is a rapidly growing field of medicine that aims to provide tailored and more precise treatment and diagnostic measures for diseases beyond the realm of cancer. Non-oncology precision medicine takes into consideration factors, such as genetics, lifestyles, and environmental conditions. Advancements in genomics, proteomics, and molecular diagnostics have enabled the recognition of important genetic variability and specific biomarkers associated with several non-cancerous conditions, allowing for more targeted approaches toward the diagnosis and management of diseases. Non-oncology precision medicine has applications in myriad therapeutic indications, including cardiovascular diseases, neurological disorders, infectious diseases, and rare genetic conditions.

The market growth is primarily attributed to the rising incidence of various disorders, such as neurological disorders, including Parkinson's disease and Alzheimer's disease, across the globe. Precision medicine is being applied to neurological diseases to identify genetic and molecular biomarkers for early diagnosis, prognosis, and tailored treatment selection. This is expected to increase the demand for non-oncology precision medicine, thereby driving market growth in the coming years.

• For instance, as of July 2024, according to the article published by the Parkinson's Foundation, around 1.0 million individuals in the U.S. are living with Parkinson's disease (PD), and the number is anticipated to rise to 1.2 million by 2030.

Moreover, rapid progress in diagnostic technologies such as genomic sequencing, high-throughput screening, and molecular diagnostics has enabled the identification of specific biomarkers and genetic variations associated with various non-oncological diseases. This is paving the way for more targeted and personalized treatment approaches, which is expected to surge the market's growth in the forthcoming years.

The COVID-19 pandemic had a significant impact on the non-oncology precision medicine market in 2020. The pandemic highlighted the need for more precise diagnosis and treatment approaches, particularly due to the diverse clinical manifestations of COVID-19. In research, precision medicine strategies were employed to understand better and manage the disease, including the use of biomarkers, genetic variants, and data about patients' environments, lifestyles, and behaviors. This significantly boosted the market growth during the pandemic.

Segmentation

Key Insights

The report covers the following key insights:

• Prevalence of Key Diseases, By Key Countries/Region, 2023


• Key Industry Developments (Mergers, Acquisitions, & Partnerships)


• New Product Launches/Approvals By Key Players


• Overview: Technological Advancements in Precision Medicine


• Impact of COVID-19 on the Market

Analysis by Type

Based on the type, the market is divided into diagnostics {next-generation sequencing (NGS), polymerase chain reaction (PCR), and others}, therapeutics { antibody-drug conjugates (ADCs), kinase inhibitors, and others}, and research {single-cell sequencing, next-generation sequencing (NGS), and others.

The diagnostics segment is projected to account for a significant share of the global non-oncology precision medicine market during the forecast period. The growth of this segment is attributed to the increasing prevalence of genetic and rare diseases. Precision diagnostic solutions are playing a vital role in enhancing preventive care and enabling early intervention. In consideration of this, the key players are increasingly offering diagnostic solutions, which are expected to boost segmental growth in the forthcoming years.

• For instance, as per the article published by the National Center for Biotechnology Information (NCBI) in January 2023, the prevalence and incidence of idiopathic pulmonary fibrosis (IPF) are increasing across the globe. Furthermore, the article stated that the adjusted rate of its prevalence in North America is 2.40 to 2.98 per 10,000 individuals. In contrast, the highest prevalence occurred in South Korea, which was around 4.51 per 10,000 persons.

On the other hand, the therapeutics segment is anticipated to grow significantly during the forecast period. The growth of the segment is attributed to the rising focus of key players in the development of targeted treatments for rare diseases. This is significantly leading to an increase in the approval of several personalized drugs for the treatment of rare diseases, which is expected to boost segmental growth in the forthcoming years.

Regional Analysis

The global market is geographically segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is expected to hold a significant share of the non-oncology precision medicine market during the forecast period. The region is witnessing a significant rise in the incidence of chronic diseases such as cardiovascular diseases and respiratory illnesses. Non-oncology precision medicine offers tailored treatments for these conditions, which is driving demand in the region and is anticipated to boost market growth. Furthermore, the region has a robust healthcare infrastructure, substantial investments in non-oncology precision medicine research, and the presence of key market players. These factors are projected to contribute to the growth of the North American non-oncology precision medicine market in the coming years.

• For instance, according to the data published by the American College of Cardiology Foundation in August 2022, projected rates of cardiovascular risk factors and disease will increase significantly in the U.S. by 2060.

Asia Pacific is projected to grow at a significant CAGR during the forecast timeframe. There is increasing awareness and acceptance of non-oncology precision medicine among patients and healthcare providers in the region. This is being driven by the high burden of chronic diseases and the growing number of clinical trials for non-oncology precision medicine being conducted in the region. Moreover, the rise in private sector investments in the region is also expected to contribute to the adoption of non-precision medicine, driving regional market growth.

• For instance, as per the article published by Healthcare Radius in August 2023, the increasing private sector investment investments in research and development are propelling the adoption of precision medicine in India.

Key Players Covered

The market consists of significant players, such as QIAGEN, AstraZeneca, Novartis AG, Teva Pharmaceutical Industries Ltd., Alnylam Pharmaceuticals, Inc., Genzyme Corporation, and Quest Diagnostics Incorporated.

Key Industry Developments

• In June 2024, Alnylam Pharmaceuticals, Inc. announced positive topline results from its HELIOS-B Phase 3 study of vutrisiran for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM).


• In October 2022, GSK plc announced a collaboration with Tempus, a precision medicine company. GSK plc will gain access to Tempus' AI-enabled platform, including its library of de-identified patient data.


• In June 2022, Alnylam Pharmaceuticals, Inc. received FDA approval for AMVUTTRA ((vutrisiran) to treat rare diseases, such as polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.